GelSana is a commercial-stage biomaterials company transforming wound care with next-generation polymer technology designed to improve healing and patient outcomes. Our first product CleraFlex launched just a few months ago and already 2026 revenue is exceeding expectations, we have signed our first major distribution agreement with a $450k minimum value over the next two years, and CleraFlex is already under review by Value Analysis Committees at four large hospital systems with strong clinical champions. This product is healing stubborn difficult wounds - it works, and demand is starting to build. To date, we’ve raised more than $6.8M in total funding: $4.3M from investors and $2.5M in non-dilutive grants. GelSana is now raising a $12M Series A to scale commercialization and accelerate growth.
$6.8M
Previous Round


CleraFlex was registered with the FDA and launched into the clinic in April 2026.
In May 2026, we signed our first major distribution agreement with Juvo Medical. This agreement has a $450k minimum value over the next two years.